Xencor has been making strides in developing its own pipeline, moving away from reliance on external partnerships. This shift is seen as a strategic move to enhance their innovation capabilities.
The company's leadership has expressed strong confidence in the potential of their in-house projects, which could lead to groundbreaking treatments in the pharmaceutical sector.
As Xencor continues to expand its pipeline, investor interest is likely to grow, reflecting a positive outlook on the company's future prospects.